Multicenter Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer; the HGCSG1401 Study

Multicenter Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer; the HGCSG1401 Study - Multicenter Retrospective Cohort Study of Regorafenib; the HGCSG1401 Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020861

Enrollment

200

Registered

2016-02-03

Start date

2014-07-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who were treated with Regorafenib. 2) Histologically confirmed colorectal adenocarcinoma 3) Unresectable metastatic or local advanced colorectal cancer 4) Age <=20 years old

Exclusion criteria

Exclusion criteria: 1) Active double cancers

Design outcomes

Primary

Measure	Time frame
Overall Survival	—

Secondary

Measure	Time frame
Progression-free survival, Response rate, Disease control rate, Time to treatment failure, Adverse events, Relative dose intensity, Detail of subsequent treatment	—

Countries

Japan

Contacts

Public ContactSatoshi Yuki

Hokkaido University Hospital Gastroenterology and Hepatology

satoshi-yuuki175@joy.ocn.ne.jp011-716-1161

Outcome results